Literature DB >> 19359498

Development of genomic reference materials for cystic fibrosis genetic testing.

Victoria M Pratt1, Michele Caggana, Christina Bridges, Arlene M Buller, Lisa DiAntonio, W Edward Highsmith, Leonard M Holtegaard, Kasinathan Muralidharan, Elizabeth M Rohlfs, Jack Tarleton, Lorraine Toji, Shannon D Barker, Lisa V Kalman.   

Abstract

The number of different laboratories that perform genetic testing for cystic fibrosis is increasing. However, there are a limited number of quality control and other reference materials available, none of which cover all of the alleles included in commercially available reagents or platforms. The alleles in many publicly available cell lines that could serve as reference materials have neither been confirmed nor characterized. The Centers for Disease Control and Prevention-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the genetic testing community as well as Coriell Cell Repositories, have characterized an extended panel of publicly available genomic DNA samples that could serve as reference materials for cystic fibrosis testing. Six cell lines [containing the following mutations: E60X (c.178G>T), 444delA (c.312delA), G178R (c.532G>C), 1812-1G>A (c.1680-1G>A), P574H (c.1721C>A), Y1092X (c.3277C>A), and M1101K (c.3302T>A)] were selected from those existing at Coriell, and seven [containing the following mutations: R75X (c.223C>T), R347H (c.1040G>A), 3876delA (c.3744delA), S549R (c.1646A>C), S549N (c.1647G>A), 3905insT (c.3773_3774insT), and I507V (c.1519A>G)] were created. The alleles in these materials were confirmed by testing in six different volunteer laboratories. These genomic DNA reference materials will be useful for quality assurance, proficiency testing, test development, and research and should help to assure the accuracy of cystic fibrosis genetic testing in the future. The reference materials described in this study are all currently available from Coriell Cell Repositories.

Entities:  

Mesh:

Year:  2009        PMID: 19359498      PMCID: PMC2671335          DOI: 10.2353/jmoldx.2009.080149

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  23 in total

1.  Successful transformation of cryopreserved lymphocytes: a resource for epidemiological studies.

Authors:  J C Beck; C M Beiswanger; E M John; E Satariano; D West
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-05       Impact factor: 4.254

2.  Cell biology. Cases of mistaken identity.

Authors:  Rhitu Chatterjee
Journal:  Science       Date:  2007-02-16       Impact factor: 47.728

3.  The Cystic Fibrosis mutation "arms race": when less is more.

Authors:  Wayne W Grody; Garry R Cutting; Michael S Watson
Journal:  Genet Med       Date:  2007-11       Impact factor: 8.822

Review 4.  The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?

Authors:  Peyton Hughes; Damian Marshall; Yvonne Reid; Helen Parkes; Cohava Gelber
Journal:  Biotechniques       Date:  2007-11       Impact factor: 1.993

5.  Frequency and clinical significance of the S1235R mutation in the cystic fibrosis transmembrane conductance regulator gene: results from a collaborative study.

Authors:  K G Monaghan; G L Feldman; G M Barbarotto; S Manji; T K Desai; K Snow
Journal:  Am J Med Genet       Date:  2000-12-11

6.  Design, development, validation, and use of synthetic nucleic acid controls for diagnostic purposes and application to cystic fibrosis testing.

Authors:  Todd M Christensen; Mohamed Jama; Victor Ponek; Elaine Lyon; Jean Amos Wilson; Marcy L Hoffmann; Bassem A Bejjani
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

Review 7.  Quality assurance in human molecular genetics testing: status and recommendations.

Authors:  Laurina O Williams; Eugene C Cole; Ira M Lubin; Norma I Iglesias; Ruth L Jordan; Lauren E Elliott
Journal:  Arch Pathol Lab Med       Date:  2003-10       Impact factor: 5.534

8.  Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel.

Authors:  R A Heim; E A Sugarman; B A Allitto
Journal:  Genet Med       Date:  2001 May-Jun       Impact factor: 8.822

9.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening.

Authors:  W W Grody; G R Cutting; K W Klinger; C S Richards; M S Watson; R J Desnick
Journal:  Genet Med       Date:  2001 Mar-Apr       Impact factor: 8.822

10.  Extensive sequencing of the cystic fibrosis transmembrane regulator gene: assay validation and unexpected benefits of developing a comprehensive test.

Authors:  Charles M Strom; Donghui Huang; Christina Chen; Arlene Buller; Mei Peng; Franklin Quan; Joy Redman; Weimin Sun
Journal:  Genet Med       Date:  2003 Jan-Feb       Impact factor: 8.822

View more
  15 in total

1.  CFTR mutation analysis and haplotype associations in CF patients.

Authors:  S K Cordovado; M Hendrix; C N Greene; S Mochal; M C Earley; P M Farrell; M Kharrazi; W H Hannon; P W Mueller
Journal:  Mol Genet Metab       Date:  2011-10-26       Impact factor: 4.797

2.  Cystic fibrosis testing comes of age.

Authors:  Wayne W Grody
Journal:  J Mol Diagn       Date:  2009-04-09       Impact factor: 5.568

3.  Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing.

Authors:  Shannon D Barker; Sherri Bale; Jessica Booker; Arlene Buller; Soma Das; Kenneth Friedman; Andrew K Godwin; Wayne W Grody; Edward Highsmith; Jeffery A Kant; Elaine Lyon; Rong Mao; Kristin G Monaghan; Deborah A Payne; Victoria M Pratt; Iris Schrijver; Antony E Shrimpton; Elaine Spector; Milhan Telatar; Lorraine Toji; Karen Weck; Barbara Zehnbauer; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2009-09-18       Impact factor: 5.568

4.  Development of genomic DNA reference materials for genetic testing of disorders common in people of ashkenazi jewish descent.

Authors:  Lisa Kalman; Jean Amos Wilson; Arlene Buller; John Dixon; Lisa Edelmann; Louis Geller; William Edward Highsmith; Leonard Holtegaard; Ruth Kornreich; Elizabeth M Rohlfs; Toby L Payeur; Tina Sellers; Lorraine Toji; Kasinathan Muralidharan
Journal:  J Mol Diagn       Date:  2009-10-08       Impact factor: 5.568

Review 5.  Reference standards for next-generation sequencing.

Authors:  Simon A Hardwick; Ira W Deveson; Tim R Mercer
Journal:  Nat Rev Genet       Date:  2017-06-19       Impact factor: 53.242

6.  Bridging the gap: moving predictive and prognostic assays from research to clinical use.

Authors:  P Michael Williams; Tracy G Lively; J Milburn Jessup; Barbara A Conley
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

7.  Mutation analysis of SLC26A4 for Pendred syndrome and nonsyndromic hearing loss by high-resolution melting.

Authors:  Neng Chen; Lisbeth Tranebjærg; Nanna Dahl Rendtorff; Iris Schrijver
Journal:  J Mol Diagn       Date:  2011-04-29       Impact factor: 5.568

Review 8.  MRI findings of obstructive azoospermia: lesions in and out of pelvic cavity.

Authors:  Huanjun Wang; Yang Peng; Wenhao Fu; Xiaoxiao Hu; Chang Li; Jian Guan
Journal:  Abdom Radiol (NY)       Date:  2020-03

9.  Molecular genetic testing for cystic fibrosis: laboratory performance on the College of American Pathologists external proficiency surveys.

Authors:  Elaine Lyon; Iris Schrijver; Karen E Weck; Andrea Ferreira-Gonzalez; C Sue Richards; Glenn E Palomaki
Journal:  Genet Med       Date:  2014-07-31       Impact factor: 8.822

Review 10.  Review of Azoospermia.

Authors:  Matthew Wosnitzer; Marc Goldstein; Matthew P Hardy
Journal:  Spermatogenesis       Date:  2014-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.